Across the SURMOUNT trials, alopecia was reported in approximately 4% to 5% of participants receiving tirzepatide
Popular in sports and recovery beverages Integrated into weight-loss and energy drink formulations Strong adoption in low-calorie, clean-label drinks By End-Use Segment, Fat Loss Accounts for 38% of the Market Share Fat loss remains the most prominent end-use category with a 38% market share
Months or even years after a viral infection, many individuals find themselves battling an invisible, unrelenting exhaustion that fundamentally alters their quality of life
Pain relief, tissue regeneration beyond cartilage, and heart health applications
Cox HD, Lopes F, Woldemariam GA, Becker JO, Parkin MC, Thomas A, Butch AW, Cowan DA, Thevis M, Bowers LD, Hoofnagle AN